EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Biomarker-Based Eligibility for Lung Cancer Screening

Hana Zahed, Xiaoshuang Feng, Karine Alcala, Karl Smith-Byrne, Elham Moez, Florence Guida, Demetrius Albanes, Stephanie J Weinstein, Alan A Arslan, Qiuyin Cai, Xiao-Ou Shu, Wei Zheng und 24 weitere

JAMA · 28.07.2026 · 336 (4) · 323

DOI: 10.1001/jama.2026.8044 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift JAMA, erschienen am 28.07.2026. Verfasst von Hana Zahed und 35 weiteren Autor:innen. Beteiligte Einrichtung: Early Detection, Prevention, and Infections Branch (EPR), International Agency for Research on Cancer, Lyon, France. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Early Detection of Cancer, Lung Neoplasms, Tomography, X-Ray Computed. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: World Health Organization, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Screening by low-dose computed tomography can reduce lung cancer mortality among high-risk individuals, but many lung cancers occur among individuals with a smoking history who are not eligible for screening.

Objective

To develop and validate the protein-based Integrative Analysis of Lung Cancer Risk and Etiology (INTEGRAL)–Risk model in individuals with a smoking history from the general population. Design, Setting, and Participants Cohorts in the Lung Cancer Cohort Consortium recruited research participants in the US, Europe, Asia, and Australia between 1985 and 2009, who were followed up for lung cancer and other health outcomes until 2021. Fourteen case cohorts of 3695 participants with a smoking history within the Lung Cancer Cohort Consortium, including 2305 randomly sampled participants and 1390 patients diagnosed with lung cancer within 3 years after blood sample collection, were designed. Plasma or serum samples from each participant were assayed using the INTEGRAL protein panel in 2022. The INTEGRAL-Risk model was trained using 7 predefined case cohorts (training set; n = 1951) to estimate absolute risk of being diagnosed with lung cancer based on age, smoking history, and 13 proteins. The validity of the INTEGRAL-Risk model was assessed in 7 independent case cohorts (testing set; n = 1744) at 1, 2, and 3 years after blood collection. Exposure Absolute risk estimates from the protein-based INTEGRAL-Risk model. Main Outcomes and Measures The primary outcome was the validity of the INTEGRAL-Risk model in the testing set with respect to discrimination (area under the curve [AUC]) and calibration (ratio of expected-to-observed cases [E/O]).

Results

A total of 3695 participants were included, with 1951 participants (including 807 with lung cancer) in the training set and 1744 participants (including 583 with lung cancer) in the testing set. In the combined 14 training and testing sets, after application of statistical weights, 323 570 participants were represented (185 016 [57%] female; median [IQR] age, 60 [51-67] years). In the independent testing set, discrimination of the INTEGRAL-Risk model was highest at 1 year of follow-up and exceeded that of the questionnaire-based PLCOm2012 (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) model (INTEGRAL-Risk AUC of 0.88 [95% CI, 0.85-0.91] vs PLCOm2012 AUC of 0.79 [95% CI, 0.75-0.83]; P value for difference <.001). Using a risk threshold to achieve the same specificity as US Preventive Services Task Force (USPSTF) 2021 criteria, the INTEGRAL-Risk model captured 85% of lung cancer cases compared with 63% by USPSTF 2021 and 70% by PLCOm2012. Discrimination of the INTEGRAL-Risk model decreased with longer prediction horizons, with a 2-year AUC of 0.84 (95% CI, 0.81-0.86) and 3-year AUC of 0.81 (95% CI, 0.79-0.83). The model was well calibrated (E/O over 3 years, 0.87 [95% CI, 0.69-1.14]). Conclusions and Relevance Compared with questionnaire-based approaches, the protein-based INTEGRAL-Risk model improved short-term prediction of lung cancer in people with a smoking history. This model has potential to improve selection of high-risk individuals who are most likely to benefit from lung cancer screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorEarly Detection of CancerLung NeoplasmsTomography, X-Ray ComputedEligibility DeterminationAgedFemaleHumansMaleMiddle AgedRisk AssessmentSmokingSmokersFollow-Up StudiesEx-SmokersUnited States

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Early Detection, Prevention, and Infections Branch (EPR), International Agency for Research on Cancer, Lyon, France.
  • Oxford Population Health, Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
  • Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
  • Environment and Lifestyle Epidemiology Branch (ENV), International Agency for Research on Cancer, Lyon, France.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
  • Department of Obstetrics and Gynecology, New York University Grossman School of Medicine, New York, New York.

Förderung

  • World Health Organization
  • NCI NIH HHS

Zitieren

APA

Zahed, H., Feng, X., Alcala, K., Smith-Byrne, K., Moez, E., Guida, F., Albanes, D., Weinstein, S. J., Arslan, A. A., Cai, Q., Shu, X. O., Zheng, W., Chen, C., Triplette, M., Tinker, L. F., Langhammer, A., Nøst, T. H., Hveem, K., Milne, R. L., …, & Johansson, M. (2026). Biomarker-Based Eligibility for Lung Cancer Screening. JAMA, 336(4), 323. https://doi.org/10.1001/jama.2026.8044

Vancouver

Zahed H, Feng X, Alcala K, Smith-Byrne K, Moez E, Guida F, et al. Biomarker-Based Eligibility for Lung Cancer Screening. JAMA. 2026;336(4):323. doi:10.1001/jama.2026.8044

BibTeX
@article{Zahed2026,
  author = {Zahed, Hana and Feng, Xiaoshuang and Alcala, Karine and Smith-Byrne, Karl and Moez, Elham and Guida, Florence and Albanes, Demetrius and Weinstein, Stephanie J and Arslan, Alan A and Cai, Qiuyin and Shu, Xiao-Ou and Zheng, Wei and Chen, Chu and Triplette, Matthew and Tinker, Lesley F and Langhammer, Arnulf and Nøst, Therese Haugdahl and Hveem, Kristian and Milne, Roger L and Bassett, Julie K and Sheikh, Mahdi and Malekzadeh, Reza and Wang, Ying and Patel, Alpa V and Visvanathan, Kala and Yuan, Jian-Min and Wang, Renwei and Koh, Woon-Puay and Sesso, Howard D and Zhang, Xuehong and Johansson, Mikael B and Amos, Christopher and Hung, Rayjean J and Muller, David and Robbins, Hilary A and Johansson, Mattias},
  title = {Biomarker-Based Eligibility for Lung Cancer Screening},
  journal = {JAMA},
  year = {2026},
  volume = {336},
  number = {4},
  pages = {323},
  doi = {10.1001/jama.2026.8044}
}
Kostenlos starten →